Abstract
Dopamine β-monooxygenase (DBM) catalyses the conversion of dopamine to norepinephrine in the catecholamine biosynthetic pathway. The substrate specificity of DBM is wide and the enzyme is capable of performing a variety of oxidations. While the crystal structure of DBM is not yet available, various indirect data allow insight into the enzymes machinery. Considered an attractive therapeutic target for the treatment of hypertension and congestive heart failure, DBM and its inhibitors have received attention by medicinal chemists over the last four decades. Although several QSAR models for DBM inhibitors have been generated, these models are actually unable to explain the exceptionally high potency of the latest generation of inhibitors.
Keywords: Dopamine β-monooxygenase, dopamine β-hydroxylase, inhibitor, imidazolethione, nepicastat, BIA 5-453, CHF
Current Enzyme Inhibition
Title: Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Volume: 5 Issue: 1
Author(s): Alexandre Beliaev, Humberto Ferreira, David A. Learmonth and Patricio Soares-da-Silva
Affiliation:
Keywords: Dopamine β-monooxygenase, dopamine β-hydroxylase, inhibitor, imidazolethione, nepicastat, BIA 5-453, CHF
Abstract: Dopamine β-monooxygenase (DBM) catalyses the conversion of dopamine to norepinephrine in the catecholamine biosynthetic pathway. The substrate specificity of DBM is wide and the enzyme is capable of performing a variety of oxidations. While the crystal structure of DBM is not yet available, various indirect data allow insight into the enzymes machinery. Considered an attractive therapeutic target for the treatment of hypertension and congestive heart failure, DBM and its inhibitors have received attention by medicinal chemists over the last four decades. Although several QSAR models for DBM inhibitors have been generated, these models are actually unable to explain the exceptionally high potency of the latest generation of inhibitors.
Export Options
About this article
Cite this article as:
Beliaev Alexandre, Ferreira Humberto, Learmonth A. David and Soares-da-Silva Patricio, Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors, Current Enzyme Inhibition 2009; 5 (1) . https://dx.doi.org/10.2174/157340809787314265
DOI https://dx.doi.org/10.2174/157340809787314265 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
CNS & Neurological Disorders - Drug Targets Viscosupplementation with Intra-Articular Hyaluronic Acid for Treatment of Osteoarthritis in the Elderly
Current Pharmaceutical Design Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Association of Zinc and Copper Status with Cardiovascular Diseases and their Assessment Methods: A Review Study
Mini-Reviews in Medicinal Chemistry Diagnoses of Gastrointestinal Cancers After Gastrointestinal Bleeding in Patients Receiving Clopidogrel or Warfarin
Current Drug Safety Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Novel Anti-inflammatory Interleukin-35 as an Emerging Target for Antiatherosclerotic Therapy
Current Pharmaceutical Design FK506 and Its Analogs - Therapeutic Potential for Neurological Disorders
Current Drug Targets - CNS & Neurological Disorders Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews MicroRNAs and the Heart: Small Things Do Matter
Current Topics in Medicinal Chemistry FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy